| |
| Alle Journale wurden nach Moxonidin durchsucht |
Treffer 1 - 16 von 16 |
|
|
|---|
1. Sanjuliani AF;
Francischetti EA;
Genelhu de Abreu V;
Ueleres Braga J
Effects of Moxonidine on the Sympathetic Nervous System, Blood Pressure, Plasma Renin Activity, Plasma Aldosterone, Leptin, and Metabolic Profile in Obese Hypertensive Patients
Moxonidine - Effect
Journal of Clinical and Basic Cardiology 2004; 7 (1-4): 19-25
Effect of monoxidine at week 24 of on (a) standing plasma noradrenaline, (b) plasma leptin and (c) fasting plasma insulin interacting
with blood pressure response responder and non-responder patients. NA: noradrenaline.
‡ p < 0.003 vs responders, * p < 0.05 vs responders. Keywords: blood pressure,
diagram,
moxonidine
|
|
|
2. Sanjuliani AF;
Francischetti EA;
Genelhu de Abreu V;
Ueleres Braga J
Effects of Moxonidine on the Sympathetic Nervous System, Blood Pressure, Plasma Renin Activity, Plasma Aldosterone, Leptin, and Metabolic Profile in Obese Hypertensive Patients
Moxonidine - Clinical evaluation
Journal of Clinical and Basic Cardiology 2004; 7 (1-4): 19-25
Study flow chart. Clinical evaluation: all visits; ambulatory blood pressure: visit 1 and 7; venous and arterial blood sample for assessment of catecholamines, insulin, glucose, leptin, plasma
renin activity, plama aldosterone, total cholesterol, triglycerides, HDL-C and LDL-C: visit 1, 4 and 7. Keywords: flowchart,
moxonidine,
study
|
|
|
3. Hitzenberger G
Kausaler Ansatzpunkt Sympathikus: Der Imidazolinrezeptoragonist Moxonidin
Moxonidin - Wirkung
Journal für Hypertonie - Austrian Journal of Hypertension 2003; 7 (1): 7-10
Effekt einer Einzeldosis von Moxonidin (0,25 mg oral, graue Balken) gegenüber Placebo (weiße Balken) 6 h nach Verabreichung (n = 8) (nach [6]) Keywords: Adrenalin,
Diagramm,
Hypertonie,
Imidazolinrezeptoragonist,
Moxonidin,
Noradrenalin,
Plasma-Renin-Aktivität,
Sympathikus,
Wirkung
|
|
|
4. Hitzenberger G
Kausaler Ansatzpunkt Sympathikus: Der Imidazolinrezeptoragonist Moxonidin
Antihypertensiva
Journal für Hypertonie - Austrian Journal of Hypertension 2003; 7 (1): 7-10
Wirkmechanismen zentralwirksamer Antihypertenisva Keywords: Antihypertensivum,
Hypertonie,
Schema,
Wirkmechanismus
|
|
|
5. Hitzenberger G
Kausaler Ansatzpunkt Sympathikus: Der Imidazolinrezeptoragonist Moxonidin
Metabolisches Syndrom - sympathische Überaktivität
Journal für Hypertonie - Austrian Journal of Hypertension 2003; 7 (1): 7-10
Postulierte Rolle der sympathischen Überaktivität für die Pathogenese des metabolischen Syndroms (nach [14]) Keywords: Hypertonie,
Metabolisches Syndrom,
Pathogenese,
Schema,
sympathische Überaktivität
|
|
|
6. Prichard BNC;
Hughes PR;
Jäger CA;
Küster LJ;
Verboom CN
Dose Relation of Blood Pressure Reduction with Moxonidine: Findings from Three Placebo- and Active-Controlled Randomized Studies
Hypertonie - Moxonidin
Journal of Clinical and Basic Cardiology 2003; 6 (1-4): 49-51
Dose-response of reduction in office sitting diastolic blood pressure (SiDBP) at trough with moxonidine. Data illustrate placebocorrected least mean squares changes with 95 % confidence intervals
(not simple means, as shown in Table 2). Keywords: diagram,
Diagramm,
hypertension,
Hypertonie,
Moxonidin,
moxonidine,
Physiotens,
Physiotens,
reduction,
Reduktion,
Studie,
study
|
|
|
7. Wenzel RR;
Baumgart D;
Bruck H;
Erbel R;
Heemann U;
Mitchell A;
Philipp Th;
Schaefers RF
Interaction of the Sympathetic Nervous System with other Pressor Systems in Antihypertensive Therapy
Moxonidin - Herzfrequenz
Journal of Clinical and Basic Cardiology 2001; 4 (3): 185-192
Effect of the central sympathicolytic moxonidine on heart rate (Details see text). Modified from reference [127] Keywords: Diagramm,
heart rate,
Herzfrequenz,
Moxonidin,
moxonidine
|
|
|
8. Wenzel RR;
Baumgart D;
Bruck H;
Erbel R;
Heemann U;
Mitchell A;
Philipp Th;
Schaefers RF
Interaction of the Sympathetic Nervous System with other Pressor Systems in Antihypertensive Therapy
Moxonidin - SNS-Überaktivität
Journal of Clinical and Basic Cardiology 2001; 4 (3): 185-192
Effect of the central sympathicolytic moxonidine on central SNS activity (muscle sympathetic nerve activity) as assessed by microneurography. Modified from reference [127] Keywords: Activity,
Aktivität,
Diagramm,
Microneurography,
Mikroneurographie,
Moxonidin,
moxonidine,
sympathetic nervous system,
Sympathikus,
sympathisches Nervensystem
|
|
|
9. Rump LC
The Role of Sympathetic Nervous Activity in Chronic Renal Failure
Noradrenalinfreisetzung - Moxonidin
Journal of Clinical and Basic Cardiology 2001; 4 (3): 179-182
A: Fractional noradrenaline (NA) release from superfused kidney slices of subtotally nephrectomised and control (sham) rats B: Albuminuria in controls, subtotally nephrectomised with and without moxonidine treatment [13] Keywords: Albuminuria,
Albuminurie,
Diagramm,
kidney,
Moxonidin,
moxonidine,
Nephrectomy,
Nephrektomie,
Niere,
Noradrenalin,
Noradrenalin
|
|
|
10. Borchard U
The Role of the Sympathetic Nervous System in Cardiovascular Disease
Imidazolinantagonisten
Journal of Clinical and Basic Cardiology 2001; 4 (3): 175-177
There is a strong correlation between the affinity of different I1-agonists at the I1-receptor in the ventrolateral medulla (VLM) and the oral dose needed to lower blood pressure in hypertensive patients. There is no such correlation for Ki at a2-receptors (modified according to [15]) Keywords: Antagonist,
Antagonist,
blood pressure,
Blutdruck,
Clonidin,
Diagramm,
hypertension,
Hypertonie,
Imidazolin,
Imidazoline,
Lofexidin,
Medulla,
Medulla,
Moxonidin,
Receptor,
Rezeptor,
Rilmenidin
|
|
|
11. Borchard U
The Role of the Sympathetic Nervous System in Cardiovascular Disease
Moxonidin - Imidazolinrezeptor
Journal of Clinical and Basic Cardiology 2001; 4 (3): 175-177
Moxonidine selectively stimulates I1-receptors in the rostral ventrolateral medulla (RVLM). The sympathetic outflow from the RVLM to the periphery is decreased. Keywords: Imidazolin,
Imidazoline,
Medulla,
Medulla,
Moxonidin,
moxonidine,
Receptor,
Rezeptor,
Schema,
Stimulation,
Stimulation
|
|
|
12. Haczynski J;
Flasinski J;
Przewlocka-Kosmala M;
Spring A
Effect of moxonidine on left ventricular hypertrophy in hypertensive patients
Moxonidin - linksventrikuläre Masse
Journal of Clinical and Basic Cardiology 2001; 4 (1): 61-65
Left ventricular (LV) mass at baseline (visit 1) and after 3 month (visit 5), 6 month (visit 6) and 9 month (visit 7) moxonidine monotherapy. Keywords: Diagramm,
left ventricular mass,
linksventrikuläre Masse,
Moxonidin,
moxonidine
|
|
|
13. Haczynski J;
Flasinski J;
Przewlocka-Kosmala M;
Spring A
Effect of moxonidine on left ventricular hypertrophy in hypertensive patients
Moxonidin - enddiastolischer Durchmesser
Journal of Clinical and Basic Cardiology 2001; 4 (1): 61-65
Left ventricular end-diastolic diameter (LV EDD) at baseline (visit 1) and after 3 month (visit 5), 6 month (visit 6) and 9 month (visit 7) moxonidine monotherapy. Keywords: Diagramm,
left ventricular end-diastolid diameter,
linksventrikulärer enddiastolischer Durchmesser,
Moxonidin,
moxonidine
|
|
|
14. Haczynski J;
Flasinski J;
Przewlocka-Kosmala M;
Spring A
Effect of moxonidine on left ventricular hypertrophy in hypertensive patients
Moxonidin - enddiastolischer Durchmesser
Journal of Clinical and Basic Cardiology 2001; 4 (1): 61-65
Left ventricular posterior wall end-diastolic diameter (PW EDD) at baseline (visit 1) and after 3 month (visit 5), 6 month (visit 6) and 9 month (visit 7) moxonidine monotherapy Keywords: Diagramm,
end-diastolic diameter,
Enddiastolischer Durchmesser,
left ventricular posterior wall,
linksventrikuläre Hinterwand,
Moxonidin,
moxonidine
|
|
|
15. Haczynski J;
Flasinski J;
Przewlocka-Kosmala M;
Spring A
Effect of moxonidine on left ventricular hypertrophy in hypertensive patients
Moxonidin - enddiastolischer Durchmesser
Journal of Clinical and Basic Cardiology 2001; 4 (1): 61-65
Interventricular septum end-diastolic diameter (IVS EDD) at baseline (visit 1) and after 3 month (visit 5), 6 month (visit 6) and 9 months (visit 7) moxonidine monotherapy. Keywords: Diagramm,
end-diastolic diameter,
Enddiastolischer Durchmesser,
interventricular septum,
Interventrikuläres Septum,
Moxonidin,
moxonidine
|
|
|
16. Waters J;
Ashford J;
Jäger B;
Verboom CN;
Wonnacott S
Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension - results of the TOPIC (Trial Of Physiotens In Combination) Study
TOPIC-Studie - Design
Journal of Clinical and Basic Cardiology 1999; 2 (2): 219-224
Study plan for TOPIC. A = placebo run-in phase (4 weeks; n = 792). B = open-label monotherapy phase (8 weeks; n = 678; moxonidine 200 mcg/day for 4 weeks, then 200 or 400 mcg/day as required). C = moxonidine monotherapy (4 weeks; n = 303; moxonidine 200 or 400 mcg/day as required for 4 weeks). D, E, F = combination therapy (4 weeks; moxonidine [400 mcg/day] plus other agent as specified below). D = moxonidine plus amlodipine (5 mg/day) (n = 87). E = moxonidine plus enalapril (10 mg/day) (n = 88). F = moxonidine plus hydrochlorothiazide (12.5 mg/day) (n = 97). Keywords: Amlodipin,
amlodipine,
Design,
Design,
Hydrochlorothiazid,
hydrochlorothiazide,
Moxonidin,
moxonidine,
Schema,
Studie,
study,
TOPIC,
TOPIC
|
|
|
| |
|
Suche Medizinische Publikationen
Suche Abbildungen und Grafiken
Medizinprodukte - Labortechnik
Antidotarium (Stand 2012)
Phytokodex (Stand 2012)
Fachbücher
Patientenliteratur
